» Articles » PMID: 7094982

The Long-term Effect of Verapamil on Plasma Digoxin Concentration and Renal Digoxin Clearance in Healthy Subjects

Overview
Specialty Pharmacology
Date 1982 Jan 1
PMID 7094982
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Single-dose investigations in healthy subjects have demonstrated substantial impairment of renal and extrarenal clearance of digoxin during coadministration of verapamil. A longitudinal study has been performed to assess the changes in digoxin disposition during long-term verapamil therapy. After one week of verapamil 240 mg/d mean plasma digoxin had risen from 0.21 +/- 0.01 ng/ml (SE) to 0.34 +/- 0.01 ng/ml(p less than 0.01), and renal digoxin clearance had fallen from 197.57 +/- 17.37 ml/min to 128.20 +/- 10.33 ml/min (p less than 0.001). These changes gradually subsided, and after six weeks, renal digoxin clearance had normalized and plasma digoxin had declined to 0.27 +/0 0.02 ng/ml (NS). The 24-h urinary recovery of digoxin increased from 46.46 +/- 3.23% before to 69.78 +/- 3.69% (p less than 0.001) after six weeks of verapamil co-administration, and this elevation persisted throughout the study. The verapamil-induced suppression of renal digoxin elimination disappears over a few weeks of drug exposure, whereas the inhibition of the extrarenal clearance of digoxin seems to persist.

Citing Articles

Non-Nutritive Sweeteners Acesulfame Potassium and Sucralose Are Competitive Inhibitors of the Human P-glycoprotein/Multidrug Resistance Protein 1 (PGP/MDR1).

Danner L, Malard F, Valdes R, Olivier-Van Stichelen S Nutrients. 2023; 15(5).

PMID: 36904118 PMC: 10005754. DOI: 10.3390/nu15051118.


Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Jalil M, Abdullah N, Alsous M, Abu-Hammour K Eur J Drug Metab Pharmacokinet. 2021; 46(3):325-342.

PMID: 33616855 DOI: 10.1007/s13318-021-00672-6.


Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin.

Hsin C, Stoffel M, Gazzaz M, Schaeffeler E, Schwab M, Fuhr U Sci Rep. 2020; 10(1):12457.

PMID: 32719417 PMC: 7385621. DOI: 10.1038/s41598-020-69326-y.


A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies.

Hanke N, Turk D, Selzer D, Wiebe S, Fernandez E, Stopfer P Pharmaceutics. 2020; 12(6).

PMID: 32560124 PMC: 7355632. DOI: 10.3390/pharmaceutics12060556.


Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine.

Wiebe S, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A Clin Pharmacokinet. 2020; 59(12):1627-1639.

PMID: 32504272 PMC: 7716890. DOI: 10.1007/s40262-020-00907-w.


References
1.
Ford A, Aronson J, Grahame-Smith D, Carver J . The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological.... Br J Clin Pharmacol. 1979; 8(2):135-42. PMC: 1429774. DOI: 10.1111/j.1365-2125.1979.tb05811.x. View

2.
Waldorff S, Andersen J, NIELSEN O, MOLTKE E, Sorensen U, Steiness E . Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther. 1978; 24(2):162-7. DOI: 10.1002/cpt1978242162. View

3.
Pedersen K, Hastrup J, Hvidt S . The effect of quinidine on digoxin kinetics in cardiac patients. Acta Med Scand. 1980; 207(4):291-5. DOI: 10.1111/j.0954-6820.1980.tb09723.x. View

4.
Klein H, Lang R, Di Segni E, Kaplinsky E . Verapamil-digoxin interaction. N Engl J Med. 1980; 303(3):160. DOI: 10.1056/NEJM198007173030316. View

5.
Pedersen K, Hvidt S, Klitgaard N, Nielsen-Kudsk F . Digoxin-verapamil interaction. Clin Pharmacol Ther. 1981; 30(3):311-6. DOI: 10.1038/clpt.1981.165. View